Skip to main content
رجوع
Watch Compare

Artiva Biotherapeutics, Inc.

جودة البيانات: 100%
ARTV
NASDAQ Manufacturing Chemicals
KWD 9.10
▲ KWD 1.61 (21.50%)
6 months return
—
Momentum
Neutral
ROE
-60.28%

النمو

Revenue Growth (5Y)
N/A
Revenue (1Y)-100.00%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

الجودة

Return on Equity
-60.28%
أقل من متوسط القطاع (-54.47%)
ROIC-47.88%
Net MarginN/A
Op. MarginN/A

الأمان

Debt / Equity
N/A
Current Ratio11.65
Interest CoverageN/A

التقييم

PE (TTM|NTM)
-2.01 | -2.75
أقل من متوسط القطاع (-1.49)
P/B Ratio1.30
EV/EBITDAN/A
Dividend YieldN/A

Quick Summary

Key Takeaways

Short bullets derived from reported financials—not the AI summary above.

Negative free cash flow of -79.34 M

Price History

الاتجاهات المالية

السعر المستهدف للمحللين

5 محللين
Buy
+86.8%
upside to target
الحالي
KWD 9.10
Consensus Target
KWD 17.00
KWD 10.00
أدنى
KWD 23.00
أعلى
التوقعات
مكرر الربحية المستقبلي
-2.75
ربحية السهم المستقبلية
-KWD 2.48
الإيرادات المقدّرة
0.0

مفاجآت الأرباح

EPS
Reported Estimate Forecast
Next: Q1 2026 · EPS Est: -KWD 0.84 · Rev Est: 0.0
Q12025 Q22025 Q32025 Q42025 Q1 '26 Q2 '26
Reported -KWD 0.83 -KWD 0.87 -KWD 0.88 -KWD 0.84 — —
Estimate -KWD 0.62 -KWD 0.77 -KWD 0.80 -KWD 0.80 -KWD 0.84 -KWD 0.77
المفاجأة -33.87% -12.99% -10.00% -5.00% — —

Growth

Rev 5Y: N/A · Earnings 1Y: N/A
Revenue Growth (1Y) -100.00% Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A

Profitability

ROE: -60.28% · Net Margin: N/A
Revenue (TTM) 0.0 Net Income (TTM) -83.87 M
ROE -60.28% ROA -52.70%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -79.34 M
ROIC -47.88% FCF Growth (3Y) N/A

Safety

D/E: N/A · Current: 11.65
Debt / Equity N/A Current Ratio 11.65
Interest Coverage N/A Asset Turnover 0.00
Working Capital 118.41 M Tangible Book Value 129.22 M

Dividends

Yield: N/A · Payout: N/A
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A

Valuation

P/E: -2.01 · EV/EBITDA: N/A
P/E Ratio -2.01 Forward P/E -2.75
P/B Ratio 1.30 P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -47.14%
Market Cap 168.32 M Enterprise Value 142.81 M

Per Share

EPS: -3.43 · FCF/Share: -3.21
EPS (Diluted TTM) -3.43 Revenue / Share 0.00
FCF / Share -3.21 OCF / Share -3.11
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A

Efficiency

FCF Conv: 94.60% · CapEx/Rev: N/A
CapEx / Revenue N/A FCF Conversion 94.60%
SBC-Adj. FCF -87.46 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024
Revenue 0.0 251,000.0
Net Income -83.87 M -65.37 M
EPS (Diluted) -3.43 -5.81
Gross Profit — —
Operating Income -89.81 M -67.28 M
EBITDA — —
R&D Expenses 69.54 M 50.33 M
SG&A Expenses — —
D&A 2.60 M 2.43 M
Interest Expense — —
Income Tax 0.0 0.0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024
Total Assets 130.94 M 209.58 M
Total Liabilities 20.97 M 22.94 M
Shareholders' Equity 109.97 M 186.64 M
Total Debt — —
Cash & Equivalents 26.70 M 40.24 M
Current Assets 112.67 M 188.63 M
Current Liabilities 13.09 M 12.25 M

مقارنة الأقران

مقابل وسيط قطاع Manufacturing (1605 نظير)
المقياس السهم وسيط القطاع
P/E -2.0 -1.5
P/B 1.3 1.6
ROE % -60.3 -54.5
Net Margin % — -41.5
Rev Growth 5Y % — 1.8
D/E — 0.3